Q-omics provides the consensus-scored WNT7A profile across patient tissues and cancer cell-line models. WNT7A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, WNT7A is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, WNT7A RNA expression shows 12,638 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight HNSC, and KIRC as cancer lineages where WNT7A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WNT7A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WNT7A survival associations across molecular data types. WNT7A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WNT7A RNA expression–survival associations across cancer types. High WNT7A expression shows unfavorable associations in HNSC, PAAD, STAD, LUSC and MESO, but favorable associations in KICH. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for WNT7A RNA expression.
This table summarizes WNT7A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for WNT7A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WNT7A shows lower tumor expression in KIRC, LUAD, KICH and LUSC and higher tumor expression in HNSC and THCA. The KIRC box plot shows higher WNT7A RNA expression in normal versus tumor tissue (log2 FC = −1.075, t-test p < 0.001).
This table shows molecular features associated with WNT7A in patient tissues and cancer cell lines. In patient samples, WNT7A shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, WNT7A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
